FindTrial
Sign In

The quantitative/qualitative changes of hepatocellular carcinoma cells mixed in autologous blood salvaged during liver transplantation after cancer cell filtration using a leukocyte depletion filter and cancer cell heating using a rapid fluid warmer

The quantitative/qualitative changes of hepatocellular carcinoma cells mixed in autologous blood salvaged during liver transplantation after cancer cell filtration using a leukocyte depletion filter and cancer cell heating using a rapid fluid warmer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0007207
Enrollment
60
Registered
2022-04-18
Start date
2022-09-01
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Samsung Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Hepatocelluar carcinoma patient undergoing liver transplantaion who are eligible for authotransfusion (18<75) - American society of anesthesia (ASA) class I - IV - A person who consented to the clinical trial and signed the informed consent form

Exclusion criteria

Exclusion criteria: - If there is a contraindication for autologous blood transfusion - If autologous blood transfusion is not performed - If the patient has liver cancer other than hepatocellular carcinoma (e.g. Cholangiocarcinoma or metastatic liver tumor) - Patients who did not consent to participate in the clinical trial

Design outcomes

Primary

MeasureTime frame
Quantification of circulating tumor cells—

Secondary

MeasureTime frame
Viability of circulating tumor cells;Clinical result of Survival and Recurrence states—

Countries

Korea, Republic of

Contacts

Public ContactJi-Hye Kwon

Samsung Medical Center

kwonjh0828@hanmail.net+82-2-3410-0369

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Mar 14, 2026